All active ingredients and cannabinoids in medicinal cannabis products must be manufactured from the cannabis plant only (section 8 of TGO 93).
This means that no other substances can be used to alter the chemical characteristics of the cannabinoids naturally occurring in the cannabis plant used as the starting material.
This requirement does NOT capture chemical changes that occur because of natural or environmental factors, such as drying, heating or burning. Medicinal cannabis products that contain neutral cannabidiol (CBD) and tetrahydrocannabinol (THC) after conversion from their acid forms would comply with section 8 of TGO 93.
To comply with TGO 93, medicinal cannabis products cannot contain:
the synthetic form of any cannabinoid (including, for example, the synthetic form of THC, known as dronabinol)
active ingredients from any source other than the cannabis plant
cannabinoids synthesised by chemical conversion, such as delta-8 THC derived from CBD.
The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.